A Phase 1-2 Dose-Escalating Study Evaluating the Safety and Tolerability of Istaroxime and Specific Effects on Electrocardiographic and Hemodynamic Parameters in Patients with Chronic Heart Failure with Reduced Systolic Function

American Journal of Cardiology

Volumn 99, Issue 2 SUPPL., 2007, Pages

  Ghali, Jalal K ^a   Smith, William B ^b   Torre Amione, Guillermo ^c   Haynos, William ^d   Rayburn, Barry K ^e   Amato, Antonino ^f   Zhang, Dan ^f   Cowart, Doug ^f   Valentini, Giovanni ^g   Carminati, Paolo ^g   Gheorghiade, Mihai ^h  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b New Orleans Center for Clinical Research   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Sigma Tau Pharmaceuticals Inc   (United States)

^g Sigma Tau SpA   (Italy)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ADENOSINE TRIPHOSPHATASE 2A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISOENZYME; ISTAROXIME; PLACEBO; PST 2744; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; ENERGY TRANSFER; FEMALE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE BIGEMINY; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HEART WORK; HEMODYNAMICS; HOLTER MONITORING; HUMAN; HYPESTHESIA; HYPOKALEMIA; IMPEDANCE CARDIOGRAPHY; INJECTION SITE PAIN; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PULSE PRESSURE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SARCOPLASMIC RETICULUM; SINUS ARRHYTHMIA; SYSTOLE; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; BLOOD PRESSURE; CARDIOGRAPHY, IMPEDANCE; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETIOCHOLANOLONE; FEMALE; HALF-LIFE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION;

EID: 33846225206     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.09.006     Document Type: Article

References (47)

1. Thom T., Haase N., Rosamond W., Howard V.J., Rumsfeld J., Manolio T., Zheng Z.J., Flegal K., O'Donnell C., Kittner S., et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
2. Adams Jr. K.F., Fonarow G.C., Emerman C.L., LeJemtel T.H., Costanzo M.R., Abraham W.T., Berkowitz R.L., Galvao M., and Horton D.P. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2005) 209-216
3. Fonarow G.C., Abraham W.T., Albert N.M., Gattis W.A., Gheorghiade M., Greenberg B., O'Connor C.M., Yancy C.W., and Young J. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J 148 (2004) 43-51
4. Gheorghiade M., Zannad F., Sopko G., Klein L., Pina I.L., Konstam M.A., Massie B.M., Roland E., Targum S., Collins S.P., Filippatos G., and Tavazzi L. Acute heart failure syndromes: current state and framework for future research. Circulation 112 (2005) 3958-3968
5. Burkhoff D., Maurer M.S., and Packer M. Heart failure with a normal ejection fraction: is it really a disorder of diastolic function?. Circulation 107 (2003) 656-658
6. Kass D.A., Bronzwaer J.G., and Paulus W.J. What mechanisms underlie diastolic dysfunction in heart failure?. Circ Res 94 (2004) 1533-1542
7. Kass D.A. Is heart failure with decent systole due to bad diastole?. J Card Fail 11 (2005) 188-190
8. Maurer M.S., King D.L., El-Khoury R.L., Packer M., and Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail 11 (2005) 177-187
9. Brucks S., Little W.C., Chao T., Kitzman D.W., Wesley-Farrington D., Gandhi S., and Shihabi Z.K. Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction. Am J Cardiol 95 (2005) 603-606
10. Redfield M.M., Jacobsen S.J., Burnett Jr. J.C., Mahoney D.W., Bailey K.R., and Rodeheffer R.J. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289 (2003) 194-202
11. Nieminen M.S., Bohm M., Cowie M.R., Drexler H., Filippatos G.S., Jondeau G., Hasin Y., Lopez-Sendon J., Mebazaa A., Metra M., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 384-416
12. Butler J., Forman D.E., Abraham W.T., Gottlieb S.S., Loh E., Massie B.M., O'Connor C.M., Rich M.W., Stevenson L.W., Wang Y., Young J.B., and Krumholz H.M. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 147 (2004) 331-338
13. Costanzo M.R., Heywood J., DeMarco T., Fonarow G.C., and Wynne J. Impact of renal insufficiency and chronic diuretic therapy on outcome and resource utilization in patients with acute decompensated heart failure. [abstract]. J Am Coll Cardiol 43 (2004) 180A
14. Cotter G., Weissgarten J., Metzkor E., Moshkovitz Y., Litinski I., Tavori U., Perry C., Zaidenstein R., and Golik A. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther 62 (1997) 187-193
15. Cotter G., Metzkor E., Kaluski E., Faigenberg Z., Miller R., Simovitz A., Shaham O., Marghitay D., Koren M., Blatt A., et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351 (1998) 389-393
16. Cuffe M.S., Califf R.M., Adams Jr. K.F., Benza R., Bourge R., Colucci W.S., Massie B.M., O'Connor C.M., Pina I., Quigg R., Silver M.A., and Gheorghiade M. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
17. Elkayam U., Teerlink J.R., and Binanay C. Use and impact of inotropes and vasodilator therapy during heart failure hospitalization in the ESCAPE trial. [abstract]. Circulation 110 (2004) III-515
18. Emerman C.L., Marco T., Costanzo M.R., and Peacock W. Diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. [abstract]. J Card Fail 10 (2004) S116
19. Felker G.M., Benza R.L., Chandler A.B., Leimberger J.D., Cuffe M.S., Califf R.M., Gheorghiade M., and O'Connor C.M. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41 (2003) 997-1003
20. Hasselblad V., Stough W.G., Shah M.R., Lokhnygina J.C., Burnett J.C., Gheorghiade M., Rayburn B., Adams Jr. K.F., Francis G.S., and Califf R.M. Relation between diuretic dose and outcome in a heart failure population: results of the ESCAPE trial. [abstract]. J Card Fail 11 (2005) S157
21. Mebazaa A. The SURVIVE Trial: comparison of dobutamine and levosimendan on survival in acute decompensated heart failure [abstract]. Presented at the American Heart Association Scientific Sessions; November 13-16, 2005; Dallas, Texas.
22. O'Connor C.M., Gattis W.A., Uretsky B.F., Adams Jr. K.F., McNulty S.E., Grossman S.H., McKenna W.J., Zannad F., Swedberg K., Gheorghiade M., and Califf R.M. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138 (1999) 78-86
23. Packer M. REVIVE II: multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure [abstract]. Presented at the American Heart Association Scientific Sessions; November 13-16, 2005; Dallas, Texas.
24. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
25. Sackner-Bernstein J.D., Kowalski M., Fox M., and Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905
26. Adamson P.B., Vanoli E., Mattera G.G., Germany R., Gagnol J.P., Carminati P., and Schwartz P.J. Hemodynamic effects of a new inotropic compound, PST2744, in dogs with chronic ischemic heart failure. J Cardiovasc Pharmacol 42 (2003) 169-173
27. Micheletti R., Mattera G.G., Rocchetti M., Schiavone A., Loi M.F., Zaza A., Gagnol R.J., De M.S., Melloni P., Carminati P., Bianchi G., and Ferrari P. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). J Pharmacol Exp Ther 303 (2002) 592-600
28. Barassi P., Ferrandi M., Bianchi G., and Ferrari P. Istaroxime stimulates SERCA2a activity in animal and human failing heart preparations [abstract]. J Card Fail 11 (2005) S154
29. Imai M., Gheorghiade M., Cowart D., Zhang D., Amato A., Carminati P., and Sabbah H.N. Intravenous istaroxime improves left ventricular systolic function in dogs with advanced heart failure without increasing myocardial oxygen consumption [abstract]. J Card Fail 11 (2005) S95
30. Makato I., Gheorghiade M., Cowart D., Zhang D., Amato A., Carminati P., and Sabbah H.N. Intravenous istaroxime improves left ventricular lusitropic properties in dogs with advanced heart failure [abstract]. J Card Fail 11 (2005) S154
31. Mattera G.G., Loi F., Adamson P.B., Gagnol J.P., Vanoli E., Borsini F., and Carminati P. Istaroxime, a novel luso-inotropic agent, improves cardiac function in dogs with acute LV dysfunction: a pilot study [abstract]. J Card Fail 11 (2005) S160
32. Abraham W.T., Trupp R.J., Mehra M., Lawless C., Mitchell J., Le Jemtel T.H., Smart F., Bijou R., O'Connor C.M., Yancy C.W., et al. Prospective evaluation of cardiac decompensation in patients with heart failure by impedance cardiography test: the PREDICT multicenter trial [abstract]. Circulation 110 (2004) 597
33. Barcarse E., Kazanegra R., Chen A., Chiu A., Clopton P., and Maisel A. Combination of B-type natriuretic peptide levels and non-invasive hemodynamic parameters in diagnosing congestive heart failure in the emergency department. Congest Heart Fail 10 (2004) 171-176
34. Sageman W.S., Riffenburgh R.H., and Spiess B.D. Equivalence of bioimpedance and thermodilution in measuring cardiac index after cardiac surgery. J Cardiothorac Vasc Anesth 16 (2002) 8-14
35. Van De Water J.M., Miller T.W., Vogel R.L., Mount B.E., and Dalton M.L. Impedance cardiography: the next vital sign technology?. Chest 123 (2003) 2028-2033
36. Nishimura R.A., and Tajik A.J. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol 30 (1997) 8-18
37. +-ATPase inhibitors derived from a 5α,14α-androstane scaffold as positive inotropic compounds. J Med Chem 46 (2003) 3644-3654
38. Gobbini M., and Cerri A. Digitalis-like compounds: the discovery of the O-aminoalkyloxime group as a very powerful substitute for the unsaturated γ-butyrolactone moiety. Curr Med Chem 12 (2005) 2343-2355
39. + pump inhibition: evaluation of electrophysiological mechanisms. J Pharmacol Exp Ther 305 (2003) 765-771
40. + pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride]. J Pharmacol Exp Ther 313 (2005) 207-215
41. Schillaci G., Di L.S., Coluccini M., Gonzini L., Porcu M., Pozzar F., and Maggioni A.P. A low pulse pressure is an independent predictor of mortality in heart failure: data from a large nationwide cardiology database (IN-CHF Registry). Ital Heart J 5 (2004) 892-898
42. Aronson D., Mittleman M.A., and Burger A.J. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 116 (2004) 466-473
43. Felker G.M., Leimberger J.D., Califf R.M., Cuffe M.S., Massie B.M., Adams Jr. K.F., Gheorghiade M., and O'Connor C.M. Risk stratification after hospitalization for decompensated heart failure. J Card Fail 10 (2004) 460-466
44. Fonarow G.C., Adams Jr. K.F., Abraham W.T., Yancy C.W., and Boscardin W.J. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293 (2005) 572-580
45. Lee D.S., Austin P.C., Rouleau J.L., Liu P.P., Naimark D., and Tu J.V. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290 (2003) 2581-2587
46. ++ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther 280 (1997) 247-254
47. Janssen P.M., Datz N., Zeitz O., and Hasenfuss G. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol 404 (2000) 191-199